Pediatrics

Pneumococcal conjugate vaccine safe for low-birth-weight and preterm infants

Published in Vaccine Weekly, May 15th, 2002

by Maria G. Essig, MS, ELS, senior medical writer - Researchers in the U.S. found heptavalent CRM197 pneumococcal vaccine (PCV) as safe and effective as the meningococcal type C conjugate vaccine (MCV) for protecting low-birth-weight and preterm infants against invasive pneumococcal disease.

H. Shinefield of the Kaiser Permanente Vaccine Study Center, Oakland, California and colleagues followed 37,868 infants enrolled in a randomized double blind clinical trial to compare the safety, efficacy, and immunogenicity of the PCV and MCV. Of the total number of children, 1756 were identified as low birth weight (between 750 and 2500 g) and 4340 classified as preterm (32 to 38...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2002-05-15)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry